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Abstract
Following an application from Praline i Cokolada j.d.o.o. submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Croatia, the
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on
the scientific substantiation of a health claim related to MegaNatural®-BP grape seed extract and
maintenance of normal blood pressure. The scope of the application was proposed to fall under a
health claim based on newly developed scientific evidence. MegaNatural®-BP, a grape seed extract
standardised for total phenolics, gallic acid and the catechin and epicatechin content, is sufficiently
characterised. The proposed claimed effect, maintenance of normal blood pressure (BP), is a beneficial
physiological effect. Among the two human intervention studies provided from which conclusions could
be drawn, one showed an effect of MegaNatural®-BP (300 mg/day) on BP in adults with normal and
high normal BP when consumed daily for 6 weeks, whereas the second study did not show an effect
of MegaNatural®-BP at the same daily dose consumed for 8 weeks in adults with normal and high
normal blood pressure or stage 1 hypertension. The evidence provided did not establish a plausible
mechanism by which the food could exert the claimed effect in vivo in humans. The evidence provided
is insufficient to establish a cause and effect relationship between the consumption of MegaNatural®-
BP and maintenance of normal blood pressure.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health), which are based on newly developed
scientific evidence or include a request for the protection of proprietary data, to the Community list of
permitted claims referred to in Article 13(3). According to Article 18 of this Regulation, an application
for inclusion in the Community list of permitted claims referred to in Article 13(3) shall be submitted by
the applicant to the national competent authority of a Member State, which will make the application
and any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: MegaNatural®-BP and maintenance
of normal blood pressure.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of MegaNatural® grape seed extract, a positive assessment of its safety, nor a decision on
whether MegaNatural® grape seed extract is, or is not, classified as a foodstuff. It should be noted
that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘MegaNatural®-BP grape
seed extract made entirely of California-grown grapes containing biologically active constituents: total
phenolics (90–93%), gallic acid (≥ 2%) and catechin and epicatechin (≥ 5%). The distribution of phenolic
compounds in the MegaNatural®-BP is on average 9% monomers, 69% oligomers and 22% polymers’.
Health relationship as claimed by the applicant
According to the applicant, the health effect is related to ‘maintenance of normal blood pressure
through endothelium dependent vasodilatation. The outcome variables used to establish the claimed
effect include multiple ambulatory measurements of systolic and diastolic blood pressure and elevation
of oxidized LDL in serum’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that ‘MegaNatural®-BP [is able] to elicit endothelium-dependent relaxation of
the blood vessels through its potent antioxidant activity and ability to inhibit endothelin-1 (ET-1)
synthesis’.
Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘MegaNatural®-BP helps
maintain healthy blood pressure’.
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Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is healthy adults.
The quantity of 300 mg/day is recommended.
Data provided by the applicant
The health claim application on MegaNatural®-BP and maintenance of normal blood pressure
pursuant to Article 13.5 of Regulation 1924/2006, was presented in a common and structured format
as outlined in the Scientific and technical guidance for the preparation and presentation of applications
for authorisation of health claims (EFSA NDA Panel, 2016).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
The scientific requirements for health claims related to antioxidants, oxidative damage and
cardiovascular health are outlined in a specific EFSA guidance (EFSA NDA Panel, 2018).
The application does not contain data claimed as proprietary and data claimed as confidential.
3. Assessment
The approach used by the NDA Panel for the evaluation of health claims is explained in the General
scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016). In assessing
each specific food/health relationship, which forms the basis of a health claim the NDA Panel considers
the following key criteria:
i) the food/constituent is defined and characterised;
ii) the claimed effect is based on the essentiality of a nutrient; OR the claimed effect is defined
and is a beneficial physiological effect for the target population and can be measured in vivo
in humans;
iii) a cause and effect relationship is established between the consumption of the food/constituent
and the claimed effect (for the target group under the proposed conditions of use).
Each of these three criteria needs to be assessed by the NDA Panel with a favourable outcome for
a claim to be substantiated. In addition, an unfavourable outcome of the assessment of criterion (i)
and/or (ii) precludes the scientific assessment of criterion (iii).
3.1. Characterisation of the food/constituent
The food/constituent proposed by the applicant as the subject of the health claim is
‘MegaNatural®-BP grape seed extract’.
MegaNatural®-BP is made from a blend of freshly crushed, unfermented varietal grapes (lat. Vitis
vinifera) grown in the Mission Bell Winery in Madera, California, USA. A multi-stage hot-water-based
extraction process in different pH environment is used, followed by adsorption by an adsorbent resin
(styrene divinyl benzene or trimethylolpropane trimethacrylate). This manufacturing process results in
a grape seed extract rich in procyanidolic and catechin monomers and oligomers with minimal content
of high molecular polymeric procyanidins (US Patent, 2003).
The final product is standardised for total phenolics (90–93%), gallic acid (≥ 2%) and the sum of
catechins and epicatechins (≥ 5%). The distribution of phenolic compounds in MegaNatural®-BP, as
measured by high-performance liquid chromatography (HPLC), is on average 9% monomers, 69%
oligomers and 22% polymers. The content of the standardised substances is identified by
spectrophotometry and/or HPLC-UV.
MegaNatural®-BP is sold as a powder and intended for use as an ingredient in beverages, foods
and dietary products. Information related to stability and batch to batch variability was provided.
The Panel considers that the food constituent MegaNatural®-BP, a grape seed extract standardised
for total phenolics, gallic acid and the sum of catechin and epicatechin content, which is the subject of
the health claim, is sufficiently characterised.
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3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘maintenance of normal blood pressure’. The
proposed target population is healthy adults.
‘The scientific evidence for the substantiation of health claims on the maintenance of normal BP can
be obtained from human intervention studies showing a reduction in SBP (e.g. point SBP, 24-h SBP) or
a reduction in diastolic blood pressure (DBP) (e.g. point DBP, 24-h DBP) if accompanied by a reduction
in SBP, as compared to an appropriate food/constituent or exceptionally to no intervention (e.g. control
group on usual diet). In this context, also reductions in BP within the normal range are considered
beneficial physiological effects.
Regarding the study duration, BP tends to stabilise after about 4 weeks in response to fixed
nutritional interventions. However, the time needed to reach such stabilisation may depend on the
study characteristics (e.g. appropriate run-in period) and the nature of the intervention. Evidence on
the sustainability of the effect with continuous consumption of the food/constituent over longer
periods of time (e.g. 8 weeks) should be provided.
Studies should be designed to account for intraindividual variability, and BP should be measured
using well-accepted methods according to standardised conditions and protocols (Mancia et al., 2013).
Owing to the lack of standardisation, self (home) measurement of BP (e.g. using an electronic device)
is not an appropriate method for measuring point SBP and point DBP in research settings; validation of
the device and protocols used are required. Measurement with a calibrated sphygmomanometer
(Mancia et al., 2013; Tolonen et al., 2015) is the standard method for the assessment of office BP.
Ambulatory blood pressure monitoring (ABPM) allows measuring BP over a 24-h period and
provides an insight to BP changes during everyday activities not covered by single measurements. The
ABPM is an appropriate method for measuring mean 24-h SBP and 24-h DBP.
With respect to the study population, results from studies conducted in hypertensive subjects
treated with lifestyle measures only (e.g. diet) could be used for the scientific substantiation of these
claims. However, the rationale for extrapolation of results obtained in hypertensive subjects under
treatment with blood pressure lowering medications (e.g. angiotensin converting enzyme (ACE)
inhibitors, blockers of beta adrenergic receptors, calcium channel blockers and diuretics) to the target
population for the claim should be provided and will be considered on a case-by-case basis (e.g.
evidence for a lack of interaction between the food and the medications used on the claimed effect’
(EFSA NDA Panel, 2018).
The Panel considers that maintenance of normal blood pressure is a beneficial physiological effect.
3.3. Scientific substantiation of the claimed effect
The applicant performed a literature search on 30 August 2020 in the following databases:
PubMed, ScienceDirect, Google Scholar and Embase. Keywords used for the food were: ‘grape seed
extract’, ‘grape seed polyphenols’, ‘grape juice’, ‘MegaNatural®-BP’, ‘MegaNatural-Gold’, and for the
endpoint: ‘antioxidant’, ‘atherosclerosis’, ‘blood pressure’, ‘hypertension’, ‘pre-hypertension’, ‘metabolic
syndrome’ and ‘cardiovascular diseases’. Only articles published in English language were considered.
In addition, a manual search was carried out. To retrieve pertinent published human trials the web site
www.polyphenolics.com was also searched.
The applicant submitted four human intervention studies and two meta-analyses of human
intervention studies. For the purpose of this opinion, only outcomes related to blood pressure are
discussed.
The systematic review by Zhang et al. (2016) covered 12 papers including 16 trials and the meta-
analysis published by Li et al. (2015) included 10 intervention studies in humans. The Panel notes that
most studies included in these meta-analyses were conducted with grape seed extracts and products
containing grape polyphenols other than MegaNatural®-BP. The Panel considers that no conclusions
can be drawn from these meta-analyses for the scientific substantiation of the claim.
In a randomised, double-blind, parallel, placebo-controlled, 3-arm dose-response study,
Sivaprakasapillai et al. (2009) investigated the effect of MegaNatural®-BP on BP in a group of 27
individuals with the metabolic syndrome (9 per arm, 16 women, mean age 46  3 years).
Adult subjects aged 25–80 years meeting the criteria of the National Cholesterol Education Program III
(NCEP-III) for the metabolic syndrome were included. Smoking, cardiovascular, pulmonary,
gastrointestinal and renal diseases, and chronic use of medicines were exclusion criteria. The publication
does not provide information on the recruitment procedure, the process of randomisation, the allocation
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of subjects to the study groups, the substance used as placebo, the power calculation, compliance of
subjects, or drop-outs during the study.
The participants were randomised to consume MegaNatural®-BP 300 mg/day, MegaNatural®-BP
150 mg/day or placebo (not specified). The intervention lasted 4 weeks. Mean daytime SBP and DBP,
measured by daytime 12-h ABPM at baseline and at the end of the intervention, were the primary
outcomes of the study. Only within-group statistical analysis using two-way ANOVA is reported for BP.
The Panel notes that no between-group comparisons are provided. The Panel also notes that BP at
baseline was markedly higher in the MegaNatural®-BP 150 mg group (SBP = 134  5 mmHg, DBP =
83  3 mmHg) than in the MegaNatural®-BP 300 mg (SBP = 123  4 mmHg, DBP = 74  4 mmHg) and
the placebo (SBP = 127  4 mmHg, DBP = 78  3 mmHg) groups, which suggests a randomisation
failure of the study. Upon a request from EFSA to provide correct statistical analysis, the applicant replied
that it was not possible to contact the authors of the study.
The Panel considers that no conclusions can be drawn from this study with severe limitations,
including insufficient reporting and inappropriate statistical analysis, for the scientific evaluation of the
claim.
The study by Robinson et al. (2012) was a randomised, double-blind, parallel, placebo-controlled,
two arm study in 32 participants (n = 16 in each group, mean age 52  3 years, 17 women, no drop-
outs) assessing the effect of MegaNatural®-BP on blood pressure in adults with normal and high
normal blood pressure.
Adults aged 25–80 years with normal and high normal blood pressure (prehypertension) (SBP
between 120 and 139 mmHg and DBP between 80 and 89 mmHg based on 24-h ambulatory blood
pressure monitoring (24-h ABPM)) were enrolled. Non-inclusion criteria were smoking, diagnosed
cardiovascular, gastrointestinal and renal diseases, and chronic use of medicines. Information on the
recruitment procedure, the randomisation process, and the power calculation is lacking in the
publication. Upon EFSA’s request, the applicant was unable to provide this information.
After a 2-week run-in period, the participants were randomised for an 8-week intervention into two
groups receiving one capsule/day of either MegaNatural®-BP (300 mg) or placebo (maltodextrin).
Mean daytime SBP and DBP, measured by daytime 12-h ABPM at baseline and at the end of the
intervention, were the primary outcomes of the study.
Only within-group statistical analysis using the paired Student’s t-test is reported for BP. The
Panel notes that no between-group comparisons are provided. Upon a request from EFSA to provide
correct statistical analysis, the applicant replied that it was not possible to contact the authors of the
study.
The Panel considers that no conclusions for the scientific evaluation of the claim can be drawn from
this study with severe limitations, including insufficient reporting and inappropriate statistical analysis.
In a randomised double-blind, parallel, placebo-controlled, two arm study, Ras et al. (2013)
assessed the effect of MegaNatural®-BP on blood pressure in adult subjects with normal blood
pressure with SBP from 120 to 129 mm Hg and DBP from 80 to 84 mm Hg, high normal blood
pressure (SBP ranging from 130 to 139 mm Hg or DBP ranging from 85 to 89 mm Hg) and untreated
persons with stage 1 hypertension (SBP 140-159 mmHg and DBP 90–99 mmHg).
Adults aged 35–75 years with no reported current or previous metabolic diseases, mean 6-h
ambulatory SBP ranging between 120 and 159 mmHg and DBP < 100 mmHg, and no pharmacological
treatment for hypertension, were recruited. Non-inclusion criteria were diagnosed metabolic,
cardiovascular, gastrointestinal and renal diseases.
After a run-in period, the participants were randomised on 1:1 basis to consume MegaNatural®-BP
(1 capsule – 300 mg/day) or placebo (microcrystalline cellulose – 1 capsule/day) for 8 weeks. A
stratification according to sex was used.
Sample size was calculated on 12-h daytime mean SBP measured by ABPM, the primary outcome of
the study. Assuming a within-subject variation of 30 mmHg for duplicate ABPM measurements, 70
subjects were needed to detect a mean SBP reduction of 3.7 mmHg (a = 0.05; two-sided) with a
statistical power of 80%. Secondary outcomes were plasma renin activity, platelet aggregation and
concentrations of alkyldimethylamine (ADMA), nitric oxide metabolites, and urinary phenolic acids.
Blood pressure was measured on two consecutive days at the run-in period and at the end of the
intervention (four times) by 12-h daytime ABPM at intervals of 20 min. Mean daytime SBP and DBP
were calculated for each individual as the average of all values recorded.
Data were analysed by repeated-measurements mixed-model analysis. Treatment, sex, date of
inclusion in the trial and hour of BP measurement were included as fixed factors. Age, BMI, change in
body weight, change in urinary Na and K excretion and urinary Na:K ratio were included as covariates.
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Participants were included as a random factor. The model was simplified by backward elimination:
variables were only retained when their significance was below 0.10.
A total of 70 participants were randomised (n = 35 in each group, 38 males, mean age 63.7  0.8
years). One subject dropped out during the run-in period and was replaced by a spare subject. One
participant (in the MegaNatural®-BP group) dropped out during the intervention. The compliance,
measured as the number of the capsules returned at the end of the study, was high (99.7%).
The results were provided for the 69 participants who completed the study. Mean daytime SBP
decreased from 135.8  1.9 mmHg (mean  SEM) to 130.3  1.7 mmHg in the MegaNatural®-BP
group, and from 135.7  1.7 mmHg to 132.5  1.7 mmHg in the control group during the study. In
an adjusted model, with change in mean daytime SBP adjusted for baseline values and the covariates
listed above, the change in SBP was –5.2 mmHg (95% CI; –7.7, –2.8) in the MegaNatural®-BP group
and –2.2 mmHg (95% CI; –4.7, –0.2) in the placebo group. The difference in SBP changes between
groups was –3.0 mmHg (95% CI: –6.5, 0.5; p = 0.09).
Mean daytime DBP decreased from 81.9  1.5 mmHg (mean  SEM) to 79.1  1.3 mmHg in the
MegaNatural®-BP group and from 81.1  1.2 mmHg to 80.0  1.1 mmHg in the control group. In the
adjusted model, the change in DBP was –2.5 mmHg (95% CI; –4.0, –1.0) in the MegaNatural®-BP
group and –1.1 mmHg (95% CI; –2.4, 0.4) in the placebo group. The difference in DBP changes
between groups was –1.4 mmHg (95% CI; –3.5, 0.6; p = 0.18).
The Panel considers that this study does not show an effect of MegaNatural®-BP given at doses of
300 mg/day for 8 weeks on blood pressure in people with normal and high normal blood pressure or
stage 1 hypertension.
Park et al. (2016) studied the effect of MegaNatural®-BP on blood pressure in subjects with normal
and high normal blood pressure (prehypertension) in a randomised, double-blind, parallel, placebo-
controlled, two arm study.
Adults aged 25–65 years with SBP between 120 and 139 mmHg or DBP between 80 and 89 mmHg
were enrolled. Non-inclusion criteria comprised smoking, diagnosed cardiovascular, respiratory,
gastrointestinal and renal diseases, and chronic use of medicines. Information on the recruitment
procedure and the process of allocation of subjects to the study groups is not provided in the publication.
After a 2-week run-in period, the eligible participants were randomised on a 1:1 basis to consume
either MegaNatural®-BP (300 mg/day dissolved in 355 mL of fruit juice) or placebo (same amount of
fruit juice) for 6 weeks. Subjects were followed for 4-week with no treatment thereafter.
Blood pressure was measured by 24-h ABPM at intervals of 1 h. The measurements were carried
out four times (at the screening visit, at the beginning of the intervention, and after 6 and 10 weeks).
Sample size was calculated based on the expected change difference in SBP between groups (the
exact values were not presented), with an 80% power, alpha = 0.05, and 20% attrition rate. A total of
34 subjects were estimated to be needed.
Changes in mean daytime and night-time SBP were the primary outcomes. Changes in DBP, flow-
mediated dilatation of the brachial artery, presence of slCAM-1 and concentrations of plasma lipids,
glucose, insulin, oxLDL, and phenolic compounds and metabolites were treated as secondary
outcomes.
In statistical analysis, mixed model analysis of repeated measures was performed on each outcome
variable to test the effects of treatment (MegaNatural®-BP, control) and time (weeks). The Kenward–
Roger correction and the method of restricted maximum likelihood were used in all mixed models.
In total, 36 adults were randomised (18 subjects per group) and 29 completed the 6-week
intervention (12 in the MegaNatural®-BP group and 17 in the control group, mean age 43  10 years,
15 men). The results on BP were reported for completers with successful BP measurements (n = 29
and n = 21 for daytime and night-time BP, respectively). The number of returned bottles was between
80% and 100% in both groups.
The results described below refer to the 6-week intervention period.
Daytime SBP decreased from 125.0  2.3 mmHg (mean  SEM) to 118.0  2.3 mmHg in the
MegaNatural®-BP group and increased from 125.6  1.9 mmHg to 127.0  1.9 mmHg in the control
group. The change in daytime SBP was -7.0  3.2 mmHg in the MegaNatural®-BP group and
1.4  2.1 mmHg in the control group (p = 0.003 in the mixed model). SBP values returned to baseline
at the end of the 4-week follow-up (124.1  2.0 mmHg).
Night-time SBP decreased from 112.9  2.3 mmHg (mean  SEM) to 111.5  2.5 mmHg in the
MegaNatural®-BP group and decreased from 113.1  2.0 mmHg to 111.2  2.0 mmHg in the control
group. The change in night-time SBP was –1.4  2.8 mmHg in the MegaNatural®-BP group and
–0.9  2.2 mmHg in the control group (difference not statistically significant in the mixed model).
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Daytime DBP decreased from 83.0  1.6 mmHg (mean  SEM) to 79.1  1.6 mmHg in the
MegaNatural®-BP group and increased from 82.9  1.3 mmHg to 83.6  1.3 mmHg in the control
group. The change in daytime SBP was –3.9  1.5 mmHg in the MegaNatural®-BP group and 0.7 
1.8 mmHg in the control group (difference not statistically significant in the mixed model).
Night-time DBP decreased from 73.1  1.7 mmHg (mean  SEM) to 72.6  1.9 mmHg in the
MegaNatural®-BP group and increased from 73.1  1.5 mmHg to 74.7  1.7 mmHg in the control
group. The change in night-time SBP was –0.5  1.8 mmHg in the MegaNatural®-BP group and 1.6 
1.5 mmHg in the control group (difference not statistically significant in the mixed model).
The Panel considers that this study performed in adults with normal and high normal blood
pressure showed an effect of MegaNatural®-BP given at doses of 300 mg/day for 6 weeks on daytime
(and not on night-time) SBP. The Panel notes that no effect was observed on DBP.
The Panel considers that, among the two human intervention studies submitted from which
scientific conclusion could be drawn for the scientific substantiation of the claim, one showed an effect
of MegaNatural®-BP (300 mg/day) on BP in adults with normal and high normal BP when consumed
daily for 6 weeks, whereas the second study did not show an effect of MegaNatural®-BP at the same
daily dose consumed for 8 weeks in adults with normal and high normal blood pressure or stage 1
hypertension.
Mechanism of action proposed
The applicant claims that MegaNatural®-BP elicits endothelium-dependent relaxation of the blood
vessels through its antioxidant activity and ability to inhibit endothelin-1 (ET-1) synthesis.
In vivo studies in humans
In the study described above, Park et al. (2016) measured the effect of MegaNatural®-BP at
300 mg/day given for 6 weeks on flow-mediated dilation (FMD) in subjects with high normal BP.
Despite the reported effect of MegaNatural®-BP on daytime SBP, no effect of MegaNatural®-BP was
found on endothelium-dependent FMD compared to placebo. The Panel notes that this study provides
no evidence for a mechanism by which MegaNatural®-BP could exert an effect on BP.
Vinson et al. (2001) investigated the effect of MegaNatural® Gold on the total antioxidant capacity
of plasma and lipoprotein oxidation as compared to red wine, grape juice and tocopherols. The
Panel notes that MegaNatural® Gold is not the food that is the subject of the claim and considers that
it is unclear how a change in the variables assessed could affect BP in humans.
In vitro studies
Edirisinghe et al. (2008) added MegaNatural®-BP to rabbit aortic rings suspended in organ baths
and pre-contacted with noradrenaline. The extract triggered a dose-dependent relaxation (0.1, 1.0,
10.0 and 100 lmol/L). The magnitude of the effect was similar to the effect exerted by acetylcholine
given in the same concentrations. After the removal of endothelium, the relaxation effect disappeared.
Also, prior incubation with l-NAME (NG-nitro-L-arginine methyl ester), which is a competitive endothelial
nitric oxide synthase inhibitor, suppressed the relaxation effect.
Lindbury and Corder (2002), unpublished study report) found that under in vitro conditions,
MegaNatural® showed an ability to inhibit ET-1 synthesis in a model of bovine aortic endothelial cells.
MegaNatural® incubated with the endothelial cells for 6 h caused a concentration-dependent inhibition
of ET-1 synthesis in the concentration range 40–1.25 lg/mL.
The Panel considers that there are significant limitations to these studies. For example, there is no
information on how the concentration used in these in vitro studies relates to the concentration of
MegaNatural®-BP in human serum, the profile of the active component(s) is undefined, and it is not
clear whether there are changes from metabolism by, e.g. the liver.
The Panel considers that the results of these in vitro studies do not provide sufficient evidence for a
mechanism by which MegaNatural®-BP could exert an effect on BP in vivo in humans.
The Panel considers that overall, the evidence provided did not establish a plausible mechanism by
which the food could exert the claimed effect in vivo in humans.
Weighing the evidence
In weighing the evidence, the Panel took into account that among the two human intervention
studies submitted from which scientific conclusion could be drawn for the scientific substantiation of
the claim, one showed an effect of MegaNatural®-BP (300 mg/day) on BP in adults with normal and
high normal BP when consumed daily for 6 weeks, whereas the second study did not show an effect
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of MegaNatural®-BP at the same daily dose consumed for 8 weeks in adults with normal, high normal
blood pressure or stage 1 hypertension. The Panel also took into account that the evidence provided
did not establish a plausible mechanism by which the food could exert the claimed effect in vivo in
humans.
The Panel concludes that the evidence provided is insufficient to establish a cause and effect
relationship between the consumption of MegaNatural®-BP, a grape seed extract standardised for total
phenolics, gallic acid and the sum of catechin and epicatechin content, and maintenance of normal
blood pressure.
Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, MegaNatural®-BP, grape seed extract standardised for total phenolics,
gallic acid and the sum of catechin and epicatechin content, which is the subject of the health
claim, is sufficiently characterised.
• The claimed effect proposed by the applicant is ‘maintenance of normal blood pressure’. The
target population proposed by the applicant is the adult population. Maintenance of normal
blood pressure is a beneficial physiological effect.
• The evidence provided is insufficient to establish a cause and effect relationship between the
consumption of MegaNatural®-BP, a grape seed extract standardised for total phenolics, gallic
acid and the sum of catechin and epicatechin content, and maintenance of normal blood
pressure.
Documentation as provided to EFSA
Health claim application on pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial
No: 0501_HR). Submitted by Praline i Cokolada j.d.o.o., Glavna ulica 64c, 10360 Sesvete, Croatia.
Steps taken by EFSA
1) This application was received by EFSA on 30/10/2020.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 2/03/2021.
4) On 15/04/2021, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The scientific
evaluation was suspended on 5/05/2021 and was restarted on 16/05/2021, in compliance with
Article 18(3) of Regulation (EC) No 1924/2006.
5) During its meeting on 6/07/2021, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to the consumption of
MegaNatural®-BP, grape seed extract standardised for total phenolics, gallic acid and the sum
of catechin and epicatechin content, and maintenance of normal blood pressure.
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Abbreviations
ABPM ambulatory blood pressure monitoring
ACE angiotensin-converting enzyme
ADMA alkyldimethylamine
ANOVA analysis of variance
BMI Body Mass Index
BP blood pressure
CI confidence interval
DBP diastolic blood pressure
ESC European Society of Cardiology
ESH European Society of Hypertension
ET-1 endothelin-1
FMD flow-mediated dilation
HPLC high-performance liquid chromatography
ICAM-1 inter cellular adhesion molecule
l-NAME NG-nitro-L-arginine methyl ester
LDL low-density lipoprotein
NCEP-III National Cholesterol Education Program III
NDA Panel on Nutrition, Novel Foods and Food Allergens
SBP systolic blood pressure
SEM standard error to the mean
UV ultraviolet
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